Core Viewpoint - The article discusses the journey and insights of Lü Qiang, the founder of Jinfang Pharmaceutical, highlighting the challenges and strategies in the innovative drug development landscape in China, particularly focusing on the RAS target and the company's approach to commercialization and investor relations. Group 1: Company Overview - Jinfang Pharmaceutical was founded in August 2017 by Lü Qiang in Shanghai Zhangjiang, capitalizing on the favorable conditions for innovative drug development in China [1] - The company successfully listed on the Hong Kong Stock Exchange, with its stock price increasing over 100% on the first day, but faced a subsequent decline of over 30% due to market adjustments [6] - Jinfang's lead drug, Dabotinib, is set to be the first RAS-targeted drug approved in China by August 2024, marking a significant milestone in the company's pipeline [3] Group 2: R&D Focus and Innovation - Jinfang is heavily invested in the RAS target, which has historically been considered "undruggable," with no approved drugs for over 40 years until Amgen's Lumakras received FDA approval in May 2021 [2] - The company aims to cover 80% to 90% of pancreatic cancer patients with its four RAS drugs, addressing a significant unmet need in the oncology market [11] - Lü Qiang emphasizes the importance of innovation beyond just targeting new mechanisms, advocating for a comprehensive understanding of existing research to drive breakthroughs [7][8] Group 3: Commercialization Strategy - Lü Qiang believes that the era of "single product dominance" is over, and that a product matrix approach is necessary for successful commercialization in the competitive oncology market [12] - The company has opted to partner with larger pharmaceutical firms for commercialization rather than pursuing independent sales, reflecting a strategic decision to leverage collective strengths [10] - Jinfang's strategy focuses on creating a "small but beautiful" commercial portfolio, aligning with clinical market gaps and technological advancements [12] Group 4: Market Dynamics and Future Outlook - The article notes that the Chinese biotech sector is increasingly scrutinized by professional capital, which now values the progress and breadth of R&D pipelines more than before [6] - Lü Qiang acknowledges the challenges of balancing innovation with market demands, indicating that the pressures of entrepreneurship are often underestimated [4] - The article concludes with insights on the evolving landscape of biotech and biopharma, suggesting that both sectors have distinct roles and that the current trend of high financial expectations in business development may require recalibration [13][14]

Core Viewpoint - The company has announced the adoption of its H-share option plan and H-share incentive plan aimed at providing qualified individuals with opportunities to gain equity in the company and to enhance the overall value for shareholders [1] Group 1: H-share Option Plan - The H-share option plan is designed to offer qualified participants, including employees and service providers, the chance to acquire capital equity in the company [1] - The plan aims to encourage qualified individuals to work towards enhancing the company's value and that of its shares [1] Group 2: H-share Incentive Plan - The H-share incentive plan is intended to retain, motivate, and reward qualified individuals by providing flexible compensation, remuneration, and/or benefits [1] - This plan is part of a broader strategy to align the interests of participants with those of the company and its shareholders [1]

Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595), announced the board's resolution to adopt the H-share option scheme and H-share incentive plan on November 24, 2025, aimed at providing qualified individuals with opportunities to gain equity interests in the company and to enhance the overall value for shareholders [1] Group 1 - The H-share option scheme and H-share incentive plan are collectively referred to as the "Share Scheme" [1] - The Share Scheme is designed to encourage qualified individuals, including employee participants, service providers, and related entity participants, to work towards enhancing the company's value and that of its shares [1] - The Share Scheme is expected to retain, incentivize, and reward qualified individuals, providing flexible means of compensation, remuneration, and/or benefits [1]

Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced the board's resolution to propose the adoption of an H-share buyback plan and an H-share incentive plan on November 24, 2025 [1] Group 1 - The board of Jinfang Pharmaceutical-B has made a decision regarding the implementation of a buyback plan for H-shares [1] - An incentive plan for H-shares has also been proposed by the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 股份計劃的宗旨 H股購股權計劃及H股股份激勵計劃（統稱「股份計劃」）旨在為合資格人士（包括 僱員參與者、服務提供者及關聯實體參與者）提供獲得本公司資本權益的機會， 並鼓勵合資格人士為本公司及本公司股東（「股東」）的整體利益，努力提升本公司 及其股份的價值。股份計劃預期將為本公司留任、激勵、回報合資格人士，向其 提供薪酬、酬金及/或福利提供靈活的方式。 計劃限額及服務提供者分項限額 根據H股購股權計劃將予授出的購股權所涉及的本公司H股（「H股」）將以(i)發行 及配發新H股；及/或(ii)轉讓本公司的庫存股份（如有）的方式滿足。根據H股股份 激勵計劃將予授出的股份獎勵相關的H股將由指定受託人透過以下方式取得：(i) 按面值認購本公司發行的新H股；(ii)按照本公司的指示及計劃規則的相關規定， 利用計劃資金按當時的市價通過二級市場收購； ...

（文章来源：每日经济新闻） 每经AI快讯，劲方医药-B(02595.HK)尾盘涨超8%，截至发稿，涨7.46%，报31.1港元，成交额2808.49万 港元。 ...

Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced a significant stock price increase, rising over 8% towards the end of trading, with a current price of 31.1 HKD and a trading volume of 28.08 million HKD [1] Group 1: Clinical Trial Announcement - On November 11, Jinfang Pharmaceutical announced the initiation of a Phase III clinical trial comparing the efficacy and safety/tolerability of GFH375 monotherapy versus investigator-selected chemotherapy for patients with KRAS G12D mutated metastatic pancreatic cancer [1] - The company’s prospectus indicates that GFH375 is being developed as a first-in-class oral G12D inhibitor, with plans for the monotherapy to enter Phase I/II trials by June 2024 [1] - GFH375/VS-7375 has received FDA Fast Track designation this year, allowing it to be used for first-line and subsequent treatment of locally advanced and metastatic KRAS G12D mutated PDAC patients [1] Group 2: Previous Data Presentation - Early data on GFH375 monotherapy for solid tumors was presented at prestigious international academic conferences such as ASCO and WCLC this year, through late-breaking abstracts and oral presentations [1]

Core Viewpoint - Jinfang Pharmaceutical-B (02595) experienced a significant stock price increase, rising over 8% towards the end of trading, with a current price of 31.1 HKD and a trading volume of 28.08 million HKD [1] Group 1: Clinical Trial Announcement - On November 11, Jinfang Pharmaceutical announced the initiation of a Phase III clinical trial comparing the efficacy and safety/tolerability of GFH375 monotherapy versus investigator-selected chemotherapy for patients with KRAS G12D mutated metastatic pancreatic cancer [1] - The company’s prospectus indicates that GFH375 is being developed as a first-line oral G12D inhibitor, with plans for the monotherapy to enter Phase I/II trials by June 2024 [1] - GFH375/VS-7375 has received FDA Fast Track designation this year, allowing it to be used for both first-line and subsequent treatments of locally advanced and metastatic KRAS G12D mutated PDAC patients [1] Group 2: Early Data Presentation - Early data on GFH375 monotherapy for solid tumors was presented at prestigious international academic conferences such as ASCO and WCLC this year, through late-breaking abstracts (LBA) and oral presentations [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勁方醫藥科技 ( 上海 ) 股份有限公司 （於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02595 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 324,643,020 | RMB | | 0.1 RMB | | 32,464,302 | | 增加 / 減少 (-) | | | 13,386,000 | | | RMB | | 1,338,600 | | 本月底結存 | | | 338,029,020 | RMB | | ...

Core Viewpoint - The innovative drug concept stocks experienced a significant rally on October 31, with multiple stocks reaching their daily limit up or showing substantial gains, indicating a strong market sentiment towards the pharmaceutical sector [1]. Group 1: Stock Performance - Sangfor Health (三生国健) surged by 20% to a price of 72.96 [2] - Shuyou Shen (舒泰神) increased by 14.29% to 36.47 [2] - Tuo Jing Life (透景生命) rose by 11.97% to 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69% to 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) climbed 11.06% to 99.18 [2] - Rongchang Biopharmaceutical (荣昌生物) went up by 10.87% to 98.30 [2] - Other notable gainers included Haitai Biotechnology (海特生物) at +10.33% and Weiguan Biotechnology (微感生物) at +10.19% [2]. Group 2: Hong Kong Market Performance - Fosen Pharmaceutical (福森药业) saw a remarkable increase of 53.62% to 1.060 [3] - Yingtou Biotechnology (映图生物-B) rose by 12.44% to 318.200 [3] - Yaojie Jiankang (药捷家康-B) increased by 9.45% to 190.000 [3] - Other stocks such as Innovent Biologics (信达生物) and Jinfang Pharmaceutical (劲方医药) also experienced gains of 8.18% and 8.05% respectively [3].